2015 2014
2013
2012
2011
2010
2009
2008
2007
.
16/MAR/15

Neuron Bio develops a new diagnosis method for the alzheimer's disease

• The new patented method consists of identifying a range of biomarkers from blood samples.
• It improves significantly current measurement techniques of cerebrospinal fluid and avoids more complex and invasive techniques.

Granada 16 March 2015. Neuron Bio (NEU.MC) has registered a patent for the diagnosis of the Alzheimer’s disease that is expected to be an important advance against this disease because it is a non-invasive method for the patient and it is also quick and simple done by a blood test.

The new method, based on the identification of a range of biomarkers allows to diagnose in a reliable way Alzheimer’s patients and also to anticipate the progress of the disease before clinical symptoms such as dementia appear, thus improving the efficacy of current methods (see graph). The patent achieves better results than similar tools in development by reference research centers (Stanford University, King’s College, Rochester University or the The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) (see table).

This new patent application has been possible thanks to researchers of the Neuron Bio team and the active participation of researchers from Spanish reference hospitals such as Virgen de las Nieves and Clínico of Granada, Ramón y Cajal and La Paz of Madrid. In words of the president of Neuron Bio, Dr. Fernando Valdivieso, “it is one of the major milestones of the company regarding the work we are carrying out in the last 10 years related to prevention, diagnosis and treatment of the Alzheimer’s disease. This is a clear progress in regard to current methods and ads to the diagnosis patent portfolio of the company, which uses biomarkers for the diagnosis of neurodegenerative diseases.”

The new method will facilitate clinical diagnoses of dementia due the alternative it offers using a blood sample instead of the current analysis of cerebrospinal fluid that leads the patient to an uncomfortable lumbar puncture and to longer analysis and evaluation processes.

Dr. Javier S. Burgos, CEO of Neuron Bio, stated “this tool will not only be useful for the clinical practice, but it also will be of great value for big pharmaceutical companies having compounds for the Alzheimer’s disease in clinical stages. It will allow the identification of suitable individuals to participate in assays reducing costs and evaluating their effects on the disease course, thus increasing so success possibilities of new treatments.”

The project, in which scientists and researchers of Neuron Bio have been working the last 3 years, is supported by the Technology Corporation of Andalusia CTA and financed by the regional Department of Economy, Innovation, Science and Employment of Andalusia and by the Ministry of Economy and Competitiveness of the Spanish Government.

More information:






Graph


Graph Neuron Bio

Table


Table Neuron Bio


For further information:


Malena Valdivieso
[email protected]
Tef.: +34 958 750 598
www.neuronbio.com
Neuron Bio  |  Neuron BioPharma  |   Neuron BioServices